Kirkland, Fenwick Steer Lilly's $3.2B Morphic Acquisition
Eli Lilly and Co. unveiled Monday a $3.2 billion all-cash deal to acquire biopharmaceutical company Morphic Holding Inc., which is developing oral therapies to treat Crohn's disease and other bowel chronic...To view the full article, register now.
Already a subscriber? Click here to view full article